Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.60 |
| ▸ | AKT2 | P31751 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428788 | 0.91 | AKT1 (0.50) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL1429286 | 0.91 | ALDH1A1 (0.67) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL13599904 | 0.86 | AKT1 (0.66) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL19953862 | 0.86 | AKT1 (0.66) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL5347018 | 0.86 | NPC1 (0.66) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL24479406 | 0.83 | AKT1 (0.63) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL25789353 | 0.83 | AKT1 (0.63) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL15382793 | 0.83 | AKT1 (0.63) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL22673418 | 0.83 | AKT1 (0.63) | AKT1AKT2ALDH1A1NPC1RAB9A | |
| SCHEMBL24478955 | 0.82 | AKT1 (0.61) | AKT1AKT2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292121-B1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | UNIV DORTMUND TECH (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10550114-B2 | Kinase inhibitors and their use in cancer therapy | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2020-02-04 | — | — | US | disclosed |
| US-20180354941-A1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2018-12-13 | — | — | US | disclosed |
| EP-3292121-A1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | Technische Universität Dortmund (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177746-A1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2016-11-10 | — | — | WO | disclosed |
| EP-3091016-A1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | Technische Universität Dortmund (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | AKT1 3/4885AKT2 2/4885ALDH1A1 3757/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | AKT1 3/4885AKT2 2/4885ALDH1A1 3757/4885 |
| US-10550114-B2 | Kinase inhibitors and their use in cancer therapy | MAP3K1, MAP3K19, MAP3K6 | AKT1 146/4885AKT2 282/4885ALDH1A1 1682/4885 |
| US-20180354941-A1 | KINASE INHIBITORS AND THEIR USE IN CANCER THERAPY | MAP3K1, MAP3K19, MAP3K6 | AKT1 146/4885AKT2 282/4885ALDH1A1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.